---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-26-000003"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:49:16.600652+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neurogene doses multiple participants in Embolden Rett trial; interim data mid-2026

## Summary
- Dosed multiple participants in Embolden registrational trial in Q4 2025; expect to complete dosing Q2 2026.
- Plan to present interim Phase 1/2 data (8 pediatric, 2 adolescent/adult) with >=12-month follow-up mid-2026.
- Cash runway through Q1 2028; early commercial-readiness activities underway including payor research.
- Initiated 13 U.S. clinical trial sites; presenting at J.P. Morgan Healthcare Conference on Jan 14, 2026.

## SEC filing metadata
- accession: 0001404644-26-000003
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000003/0001404644-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000003/ngne-20250811_d2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-26-000003
- JSON: https://secwatch.observer/filing/0001404644-26-000003.json
- Plain text: https://secwatch.observer/filing/0001404644-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.